Roy S. Herbst,


Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
Smilow Cancer Hospital
New Haven, CT

Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine (Medical Oncology) and professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research at Yale Cancer Center, Yale School of Medicine, and Smilow Cancer Hospital in New Haven, CT. 

Dr Herbst is a highly respected clinician­scientist who has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and to bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced-stage lung cancers. This work has led to the approval of several therapies, such as gefitinib, cetuximab, bevacizumab, axitinib, atezolizumab, and pembrolizumab, that have revolutionized the field and greatly enhanced patient survival. His work on “umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the US Food and Drug Administration. Nationally, he is at the forefront of personalized medicine and works closely with public-private partnerships to develop large clinical trials, such as Lung-MAP. He testified on the 21st Century Cures Initiative before the House of Representatives and served as a prominent figure in this area as a member of the NAM Policy Forum for 9 years. He leads the National Cancer Institute Lung Cancer SPORE (Specialized Program of Research Excellence), which has identified new mechanisms of sensitivity and resistance to immunotherapy. 

He has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has also been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. Further, Dr Herbst has authored or coauthored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, The Lancet, and The New England Journal of Medicine. His work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

Dr Herbst was a member of the National Cancer Policy Forum, for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of the American Association for Cancer Research, where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice-chair for developmental therapeutics for the SWOG Lung Committee. In 2015, his team at Yale was awarded a Lung Cancer SPORE by the National Cancer Institute, and he serves as a principal investigator for an American Association for Cancer Research/Stand Up To Cancer Dream Team grant. For his lifetime achievement in scientific contributions to thoracic cancer research, Dr Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer in Vienna, Austria.